Up next

Supplier News: Cambrex, ACG, Syngene, Sharp, SK pharmteco & More 

The latest from CDMOs, CMOs, and suppliers featuring Cambrex, ACG, Syngene, Sharp Services, SK pharmteco, ProImmune, Seran BioScience, Aenova, Adare Pharma Solutions, Stevanato Group, Wilmington PharmaTech, and Aragen 

Chemicals/Chemical API Manufacturing 
* Cambrex Investing $120 M in API Mfg Expansion  
* Syngene Adding Bioconjugation Suite & Peptide Lab 
* SK pharmteco Expanding Peptide Mfg 
* Wilmington PharmaTech Secures Funding from PE Firm 
Biologics Manufacturing 
* ProImmune Opens New HQ 
Formulation Development/Drug Product Manufacturing 
* ACG to Build $200-M Hard-Shell Capsule Mfg Facility 
* Sharp Services Investing $100 M Across US & EU Mfg Facilities
* Seran BioScience Opens New Solid Dosage Mfg Facility 
* Aenova To Expand Sterile Mfg 
Packaging 
* Adare Pharma Solutions Expands Packaging & Warehouse Facility 
* Stevanato Group Expands Mfg Facility for Drug-Delivery Systems  
Appointments 
* Aragen Appoints New CEO of Drug Discovery Business

Chemicals/Chemical API Manufacturing 

Cambrex Investing $120 M in API Mfg Expansion 
Cambrex has announced a $120-million investment to expand its US operations, which will support a 40% increase in large-scale manufacturing capacity at its site in Charles City, Iowa. The Charles City facility, situated on a 45-acre site, manufactures a broad range of APIs and pharmaceutical intermediates, including highly potent molecules and controlled substances.  

Over the past five years, the company has made other key investments in its US operations, including: 

  • The addition of highly potent API and large-scale manufacturing capacity in Charles City, Iowa (2022);  
  • New laboratories, clinical and small-to-medium volume commercial manufacturing capacity, designed for commercial therapies targeting rare diseases and orphan designations, in High Point, North Carolina (2023); and 
  • Expanded capabilities and new GMP manufacturing capacity for peptide therapeutics in Waltham, Massachusetts (2025). 

Source: Cambrex 

Syngene Adding Bioconjugation Suite & Peptide Lab 
Syngene International, a Bengaluru, India-based CDMO of small-molecule active pharmaceutical ingredients and biologics, has announced separate investments, respectively for a peptide laboratory and a bioconjugation suite. 

The investments include a dedicated peptide laboratory in Bengaluru, India, and the integration of advanced automation across DMPK (drug metabolism and pharmacokinetics) and direct-to-biology workflows at its site in Hyderabad, India. The dedicated peptide laboratory is designed to produce a wide range of molecules, including linear peptides, cyclic peptides, and peptide-drug conjugates, and supports synthesis scale-up to 800 mmol (millimole). The laboratory has six automated peptide synthesizers operating in parallel and features integrated solid-phase peptide synthesis, high-performance liquid chromatography, and liquid-phase purification, coupled with quality control laboratories. 

The company is also adding a GMP bioconjugation suite at its commercial biologics manufacturing facility in Bengaluru, India. With this new capability, Syngene will offer end-to-end services for antibody-drug conjugates (ADCs) from discovery through to GMP manufacturing. The OEB-5 rated suite will accelerate ADC development timelines by enabling both monoclonal antibodies production and GMP bioconjugation at a single site. Expected to be operational within the financial year, the conjugation facility will also support a range of advanced conjugates and related modalities.  

Source: Syngene (Peptides) & Syngene (Bioconjugation) 

SK pharmteco Expanding Peptide Mfg 
SK pharmteco, a CDMO of small-molecule active pharmaceutical ingredients (APIs) and cell and gene therapies, has announced a $6.1-million investment in its facility in Rancho Cordova, California, to expand and equip a new lab and cGMP-kilo-scale facility for solid-phase peptide synthesis and purification. The investment complements SK pharmteco’s previously announced $260-million investment in a new small molecule and peptide production facility in South Korea, announced last year (2024). 

The lab is scheduled to come on line in January 2026, and the kilo-scale facility in the second half of 2026. 

Source: SK pharmteco 

Wilmington PharmaTech Secures Funding from PE Firm 
Wilmington PharmaTech (WPT), a CDMO focused on small molecule active pharmaceutical ingredient development and manufacturing, has announced a majority investment by Curewell Capital, a private equity firm. The funding will provide growth capital to expand WPT’s manufacturing capacity and further scale its capabilities in producing small-molecule APIs in the US. 

Headquartered on a 54-acre campus in Delaware, WPT operates two adjacent facilities with cGMP manufacturing capabilities, including dedicated high-potency API suites, as well as a registered starting material support and R&D facility in Suzhou, China. 

Source: Wilmington PharmaTech 

Biologics Manufacturing 

ProImmune Opens New HQ 
ProImmune, an Oxford, UK-based producer of life-science reagents and services, has announced the opening of its new global headquarters building at Oasis Park, Oxford, UK. ProImmune’s new 18,000-square-foot main headquarters facility represents an investment in laboratories to provide space and infrastructure for the company’s Reveal Immunogenicity System, a suite of assay services to help understand immune responses to vaccines and therapeutic products, and the expansion of the company’s Ankyron target-binding reagent platform.  

Source: ProImmune 

Formulation Development/Drug Product Manufacturing 

ACG to Build $200-M Hard-Shell Capsule Mfg Facility 
ACG, a provider of oral dosage products and services, has announced a $200-million phased investment to establish its first empty-capsule manufacturing operations in the US. The initial $100 million will fund a hard-shell capsule facility in Atlanta, Georgia, with a second phase of $100 million planned to expand capacity and capabilities in the region. ACG will establish dedicated facilities to manufacture gelatin and vegetarian (HPMC) hard-shell capsules.  

The investment is expected to create more than 200 jobs, with operations targeted to begin in early 2027. ACG has North American headquarters in Piscataway, New Jersey, and manufactures liquid-fill capsules at its site in Chadds Ford, Pennsylvania, with several warehouses across the US and sales and service teams nationwide 

Source: ACG 

Sharp Services Investing $100 M Across US & EU Mfg Facilities 
Sharp Services, a provider of contract packaging, clinical supply services, and small-scale sterile manufacturing, has announced a $100-million investment across its global facility network. The investment includes: 

  • Sterile fill–finish capacity added in Lee, Massachusetts, and injectable assembly and packaging capacity added in the Netherlands, Belgium, Allentown and Macungie, Pennsylvania. 
  • New oral solid dose (OSD) bottling and pouching lines at Allentown. 
  • New clinical cold-chain capacity and OSD packaging and manufacturing at Bethlehem, Pennsylvania. 
  • New isolator-based sterile filling capacity added in Lee, Massachusetts. 

As part of this global investment strategy, in Europe, Sharp’s Netherlands facility is increasing GMP production capacity to accommodate new vial labeling, syringe assembly and injectables packaging, which is due to come on line in 2026.  In Belgium, Sharp has begun a significant warehouse expansion, which will include additional cold-chain and ambient storage and is building out a new syringe blistering production suite.

In the US, Sharp’s Allentown campus will add a new pre-filled syringe assembly, labeling and packaging line, a vial labeler and high-speed cartoner, a mid-speed bottling and packaging line for OSD products, and automated pouch-filling lines for powder and OSD products. This new equipment will add capacity to support exiting products as well as provide capacity for new opportunities.  

These investments at Allentown complement the company’s recent $20-million investment announcement for autoinjector and pen assembly services at Macungie. The plan includes installation of two autoinjector and pen assembly, labeling and packaging lines at its facility in Macungie.  

Sharp’s Bethlehem site has commenced the installation of a 2-8 °C production room with refrigerator and -15 °C to -25 °C walk-in freezer, two new capsule-filling machines and an additional blister line to package OSD products. These new clinical and commercial capabilities will be operational at the site by the end of 2025. 

Sharp has also committed $28 million to increase capacity at its sterile manufacturing facility in Lee. The investment will support the installation of a fourth isolator-based sterile filling line with lyophilization and several related infrastructural upgrades. 

Source: Sharp Services 

Seran BioScience Opens New Solid Dosage Mfg Facility 
Serán BioScience, a Bend, Oregon-based CDMO of oral solid dosage products, has announced the completion of two of three new buildings and the start of construction of a third facility at its new 100,000-square-foot commercial manufacturing campus in Bend, Oregon. The new campus will encompass a 50,000-square-foot manufacturing facility, complemented by an adjacent 50,000-square foot space dedicated to specialized packaging and supply-chain operations.  

Enabled by a new investment from Bain Capital Life Sciences in September 2024 and continuing investment from Vivo Capital, the new greenfield site enhances Serán’s ability to provide complex oral solid dosage forms. Specializing in spray drying, particle engineering, and advanced drug formulation, the US facility is purpose-built to produce commercial-scale, non-sterile solid dose products,  

Adjacent to the new plant, Serán has completed two newly constructed warehouse and light manufacturing buildings totaling 50,000 square feet. These facilities support advanced materials management, packaging, labeling, and other logistics functions. 

Source: Serán BioScience 

Aenova To Expand Sterile Mfg 
Aenova, a CDMO of drug products, has announced a major investment in its sterile manufacturing capabilities with the installation of another fill-finish line at its site in Latina, Italy, the company central sterile manufacturing site. The new fill-finish line will support a broad range of container formats, including vials ranging from 2R to 50R, pre-filled syringes from 0.5 mL to 50 mL, and pre-filled cartridges from 1 mL to 20 mL. 

The new line will operate under isolator technology. It will be capable of processing a wide range of biologics, including monoclonal antibodies, peptides, and vaccines. The line will add an annual capacity of 30 to 40 million units. In total, the Latina site will be capable of producing over 100 million units per year. 

This expansion is part of a broader investment strategy, with approximately EUR 100 million ($116 million) allocated over the next three years to enhance capacity and capabilities at the Latina site. In addition to the new line, this investment includes a cold-chain warehouse and an expanded QC laboratory. 

Source: Aenova 

Packaging 

Adare Pharma Solutions Expands Packaging & Warehouse Facility 
Adare Pharma Solutions, a CDMO of oral dose products, has completed an expansion of its Pessano facility in Milan, Italy, increasing the company’s European packaging & warehousing capacity.  

Construction of the new dedicated packaging and warehouse expansion is complete and has been authorized by AIFA, the Italian medicines agency. The facility is currently producing validation and commercial batches. 

The 2,800 square-meter packaging hall houses a Marchesini Integra 220S MA260 blister line, featuring integrated Robocombi “pick and place” and SeaVision serialization capabilities. The line is designed for high-efficiency packaging of tablets and capsules into a wide range of formats, including Aclar, Triplex, PVC, PVDC, and Alu-Alu blisters, with an annual capacity of more than 50 million blisters. 

Additionally, the new building accommodates an expanded warehouse with capacity for over 900 pallets, infrastructure to support up to four future packaging lines, and dedicated areas for manual packaging, quality control, in-process testing, and serialized materials storage. 

Source: Adare Pharma Solutions 

Stevanato Group Expands Mfg Facility for Drug-Delivery Systems 
Stevanato Group, a provider of drug-containment, drug-delivery and diagnostic products and services, has announced an expansion of its drug-delivery systems manufacturing capacity. 

As part of its footprint optimization plan, the company recently added production space for drug-delivery devices to its facility in Bad Oeynhausen, Germany, to provide more than 2,500 square meters of advanced manufacturing capacity. 

The multi-million investment includes installation of an ISO 8 cleanroom environment, fully equipped for injection molding and automated assembly operations. These upgrades enable the site to support both Stevanato Group’s proprietary device production and contract manufacturing services.  

Source: Stevanato Group 

Appointments 

Aragen Appoints New CEO of Drug Discovery Business 
Aragen, a CDMO of drug substances and drug products, has announced the appointment of Neeraj Garg, current Head of Eurofins’ India Businesses and Global Delivery Center in India, as CEO of Aragen’s Discovery Solutions business.  

In this role, he will be responsible for strategy to drive growth through organic and inorganic models, expand the company’s client base, improve operational efficiencies, and incubate new capabilities to accelerate partners’ research programs. He will be based at the company’s corporate office in Hyderabad, India, and will join Aragen’s Management Council. 

Before joining Aragen, he served as Head of Eurofins India Businesses and Global Delivery Center in India, where he successfully led the CRO business and testing operations. He also was CEO at Apollo Health & Lifestyle Limited and held senior leadership roles at Abbott Healthcare, where he developed and launched novel healthcare platforms and led global strategic planning for branded pharmaceutical products. 

Source: Aragen